RIFAFOUR e-275

PreclinicalSmall molecule

GSK

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PulmonaryCompleted

PulmonaryPreclinical

Completed

Clinical

Trials by Indication[1]

Pulmonary Tuberculosis4 trials

An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

Completed· GSK logo

GSK·Phase 2·NCT03557281·76 enrolled

Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

Completed·TTASK Applied Science·Phase 2·NCT05896930·134 enrolled

Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis

Completed· Otsuka logo

Otsuka·Phase 2·NCT00401271·54 enrolled

Show 1 more trial

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Completed· GSK logo

GSK·Phase 2·NCT05382312·127 enrolled

Phase 21 trial

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Completed·QQurient Co., Ltd.·Phase 2·NCT03563599·60 enrolled

Drug1 trial

The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)

Completed·UUniversity of Cape Town·Phase 1·NCT02953847·21 enrolled

Pulmonary1 trial

A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis

Completed·MMichael Hoelscher·Preclinical·NCT04044001·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for RIFAFOUR e-275. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RIFAFOUR e-275 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RIFAFOUR e-275. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK